Under: Fat Loss
Best Peptides for Appetite Suppression
Reducing hunger signals and caloric intake to support weight management.
Appetite suppression refers to the reduction of hunger signals and caloric intake, a mechanism being studied for weight management applications. Research peptides are being investigated for their ability to modulate appetite-regulating pathways in the hypothalamus and gastrointestinal system. Semaglutide, which mimics glucagon-like peptide-1 (GLP-1), and Retatrutide, a triple receptor agonist, are among the peptides being studied for their effects on satiety signaling and metabolic regulation. These peptides work through distinct mechanisms—such as slowing gastric emptying and enhancing insulin sensitivity—that collectively support reduced hunger perception.
Appetite suppression peptides typically follow varied dosing protocols depending on the specific compound, with administration ranging from daily subcutaneous injections to weekly dosing schedules in research settings. Timing relative to meals and consistency of dosing protocols are important variables in research studies examining their effects on hunger signals and weight management outcomes.
Peptides Studied for Appetite Suppression
| Peptide | Evidence | Notes | Actions |
|---|---|---|---|
| Retatrutide Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied. | high | — | |
| Retatrutide Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied. | high | — | |
| Semaglutide Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide. | high | — | |
| Semaglutide Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide. | high | — | |
| Tirzepatide Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials. | high | — | |
| Tirzepatide Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials. | high | — | |
| GHRP-6 Growth Hormone Releasing Peptide 6 (GHRP-6) is one of the first synthetic growth hormone secretagogues discovered. It stimulates significant GH release but is known for causing intense hunger. | low | — | |
| GHRP-6 Growth Hormone Releasing Peptide 6 (GHRP-6) is one of the first synthetic growth hormone secretagogues discovered. It stimulates significant GH release but is known for causing intense hunger. | low | — |
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.
Growth Hormone Releasing Peptide 6 (GHRP-6) is one of the first synthetic growth hormone secretagogues discovered. It stimulates significant GH release but is known for causing intense hunger.